Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 22Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Neoplasm Metastasis 2Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Primary Dysautonomias 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Specimen Handling 2Nivolumab 2talimogene laherparepvec 1pembrolizumab 1bicalutamide 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Fluorescein 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paget Disease, Extramammary × bicalutamide × 1 year × Clear all
NCT07117851 2025-08-12

A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

Fudan University

Phase 2 Recruiting
20 enrolled

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡